Natera Inc.

1 day ago · seekingalpha.com

Natera, Inc. (NTRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

3 days ago · fool.com

The sale was executed under a pre-arranged Rule 10b5-1 plan amended in March 2026, leaving Chapman with 98,199 directly held shares.

3 days ago · businesswire.com

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea. Natera and its collaborators presented four abstracts, including two oral presentations. A mini-oral presentation featured the largest molecular residual disease (MRD) dataset ever presented in lung cancer. This analysis of 1,129 patients with rese.

7 days ago · fool.com

Instead, it's -- of all things -- a medical diagnostics company. In this niche, the company has several compelling advantages.

20 days ago · businesswire.com

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients with both newly diagnosed and relapsed/refractory (R/R) lymphoma. PET/CT scans serve as the standard tool for assessing treatment response in lymphoma, but their performance is limited, with positive predictive value (PPV) reported as low as 50%.

24 days ago · zacks.com

NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.

24 days ago · businesswire.com

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a national partnership with Susan G. Komen®, the world's leading breast cancer organization. Together, the organizations aim to accelerate breast cancer awareness and education, including efforts to increase understanding of MRD. Natera's SignateraTM MRD test is supported by more than 185 peer-reviewed publications across multiple cancer types, including.

25 days ago · businesswire.com

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new Signatera collaboration with Angiex, Inc., a privately held biotech company developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs). Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells and.

27 days ago · defenseworld.net

Brandywine Managers LLC acquired a new stake in Natera, Inc. (NASDAQ: NTRA) in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 14,588 shares of the medical research company's stock, valued at approximately $3,960,000. Natera comprises about 2.0% of Brandywine Managers

1 month ago · fool.com

The hedge fund legend has bet much of the family office on this one diagnostics company.